Dr Reddy's, Sun Pharma recall products in US for manufacturing issues

Drug majors Dr Reddy's Laboratories and Sun Pharma are recalling different products in the US market for manufacturing issues, according to the US Food and Drug Administration. As per the enforcement report by the US health regulator, the US-based arm of Dr Reddy's Laboratories is recalling over 48,000 cartons of a drug used to treat sneezing, runny or stuffy nose. It is recalling 25,176 cartons of 30-count tablets and 22,968 cartons of 20-count tablets. According to USFDA, Dr Reddy's Laboratories is recalling the affected lot due to "failed stability specifications". New Jersey-based Dr Reddy's Laboratories, Inc initiated the Class III recall on November 21 this year. As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". The health regulator further said the US-based arm of Sun Pharma is recalling 14,064 cartons of a medication to treat erosive esophagitis or heartburn
04-12-2022
Bigul

About 25% of Dr Reddy's products to be first-to-market by 2027: Co-chairman GV Prasad

Also adds that the firm will provide more employment opportunities to persons with disabilities'
25-11-2022

Antitrust Litigation Filed Against Dr Reddy's Laboratories In US

Dr Reddy's Laboratories Ltd on Tuesday said it is among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed...
22-11-2022
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
22-11-2022

Dr Reddy's is now No.2 drug firm as old order changes

Aurobindo is bogged down by weak sales and price decline for its current formulation biz in US, which accounted for 46% of total sales
21-11-2022
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Copy of Newspaper Publication- Loss of Share Certificates
17-11-2022
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

This is to inform you that the Company's management will be participating in the conferences and group meetings, as attached.
16-11-2022
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Of Related Party Transactions For H1 FY23

Disclosure of Related Party Transactions for H1 FY23
11-11-2022
Next Page
Close

Let's Open Free Demat Account